Benjamin Miron

468 total citations
23 papers, 277 citations indexed

About

Benjamin Miron is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Benjamin Miron has authored 23 papers receiving a total of 277 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Surgery, 12 papers in Pulmonary and Respiratory Medicine and 9 papers in Oncology. Recurrent topics in Benjamin Miron's work include Bladder and Urothelial Cancer Treatments (10 papers), Urinary and Genital Oncology Studies (7 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Benjamin Miron is often cited by papers focused on Bladder and Urothelial Cancer Treatments (10 papers), Urinary and Genital Oncology Studies (7 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Benjamin Miron collaborates with scholars based in United States, France and Israel. Benjamin Miron's co-authors include Matthew R. Zibelman, David H. Ilson, David P. Kelsen, Douglas A. Levine, Manish A. Shah, Marinela Capanu, Jeff Boyd, Gary K. Schwartz, David S. Klimstra and Elizabeth R. Plimack and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Benjamin Miron

19 papers receiving 275 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Benjamin Miron United States 8 160 131 130 81 43 23 277
Nick van Dijk Netherlands 8 72 0.5× 151 1.2× 180 1.4× 52 0.6× 39 0.9× 16 273
Xiaoliang Zhu China 10 95 0.6× 97 0.7× 70 0.5× 103 1.3× 79 1.8× 23 239
Victoria Hinder New Zealand 7 64 0.4× 136 1.0× 109 0.8× 67 0.8× 26 0.6× 18 264
Kimiharu Takamatsu Japan 9 120 0.8× 58 0.4× 116 0.9× 44 0.5× 31 0.7× 33 240
Wenyu Zhai China 9 163 1.0× 55 0.4× 130 1.0× 39 0.5× 31 0.7× 28 241
Sarah Scagliarini Italy 7 98 0.6× 100 0.8× 41 0.3× 85 1.0× 57 1.3× 23 207
Michele Sisani Italy 7 68 0.4× 82 0.6× 49 0.4× 40 0.5× 25 0.6× 20 176
Serena Hilman United Kingdom 6 77 0.5× 144 1.1× 103 0.8× 37 0.5× 18 0.4× 20 223
Urbano Anido Herranz Spain 5 104 0.7× 90 0.7× 144 1.1× 28 0.3× 20 0.5× 16 203
Natalie Q. Wang Canada 2 111 0.7× 79 0.6× 53 0.4× 24 0.3× 28 0.7× 2 172

Countries citing papers authored by Benjamin Miron

Since Specialization
Citations

This map shows the geographic impact of Benjamin Miron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin Miron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin Miron more than expected).

Fields of papers citing papers by Benjamin Miron

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benjamin Miron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin Miron. The network helps show where Benjamin Miron may publish in the future.

Co-authorship network of co-authors of Benjamin Miron

This figure shows the co-authorship network connecting the top 25 collaborators of Benjamin Miron. A scholar is included among the top collaborators of Benjamin Miron based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benjamin Miron. Benjamin Miron is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Handorf, Elizabeth A., Pooja Ghatalia, Benjamin Miron, et al.. (2024). Survival Outcomes in Patients With Muscle-Invasive Bladder Cancer Receiving Neoadjuvant Chemotherapy Stratified by Number of Cycles. Clinical Genitourinary Cancer. 22(6). 102218–102218.
2.
Miron, Benjamin, Gerald Li, Júlia C.F. Quintanilha, et al.. (2024). Relationship of tumor fraction in circulating tumor DNA with prognosis in patients with advanced urothelial cancer. SHILAP Revista de lepidopterología. 3. 100004–100004. 5 indexed citations
3.
Saad, Eddy, Chris Labaki, Benjamin Miron, et al.. (2024). Multi-omic characterization of acquired resistance to immune checkpoint inhibitors in patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology. 42(4_suppl). 459–459.
4.
Handorf, Elizabeth A., Pooja Ghatalia, Benjamin Miron, et al.. (2023). Survival outcomes in patients with muscle-invasive bladder cancer receiving neoadjuvant chemotherapy stratified by number of cycles.. Journal of Clinical Oncology. 41(16_suppl). 4586–4586.
5.
Elliott, Andrew, Jacqueline T. Brown, Bassel Nazha, et al.. (2023). The Genomic Landscape of Urothelial Carcinoma with High and Low ERBB2 Expression. Cancers. 15(24). 5721–5721. 5 indexed citations
6.
Zarrabi, Kevin, Vivek Narayan, Patrick Mille, et al.. (2023). Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer. Therapeutic Advances in Urology. 15. 3633528715–3633528715. 18 indexed citations
7.
Bukavina, Laura, Ilaha Isali, Rashida Ginwala, et al.. (2023). Global Meta-analysis of Urine Microbiome: Colonization of Polycyclic Aromatic Hydrocarbon–degrading Bacteria Among Bladder Cancer Patients. European Urology Oncology. 6(2). 190–203. 29 indexed citations
8.
Zarrabi, Kevin, Elizabeth A. Handorf, Benjamin Miron, et al.. (2022). Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma. The Oncologist. 28(2). 157–164. 17 indexed citations
9.
Miron, Benjamin, Elizabeth A. Handorf, Kevin Zarrabi, et al.. (2022). Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors. Urologic Oncology Seminars and Original Investigations. 40(10). 454.e9–454.e16. 2 indexed citations
10.
Miron, Benjamin, Jessica E. Hawley, Daniel M. Geynisman, et al.. (2022). Clinical Trial Considerations for Bladder Preservation in Muscle-Invasive Bladder Cancer. 2(1). 213–225. 2 indexed citations
11.
Miron, Benjamin, Jean Hoffman‐Censits, John P. O’Neill, et al.. (2020). Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. European Urology Oncology. 3(4). 544–547. 54 indexed citations
12.
Miron, Benjamin, David Xu, & Matthew R. Zibelman. (2020). Biomarker Development for Metastatic Renal Cell Carcinoma: Omics, Antigens, T-cells, and Beyond. Journal of Personalized Medicine. 10(4). 225–225. 6 indexed citations
13.
Miron, Benjamin, Donald E. Henson, David Arguello, et al.. (2019). Non-urothelial bladder cancer: Genomic alterations and patient outcomes.. Journal of Clinical Oncology. 37(7_suppl). 399–399. 2 indexed citations
14.
Kamal, Maud, Gabi Tarcic, Sylvain Dureau, et al.. (2018). Revisited analysis of a SHIVA01 trial cohort using functional mutational analyses successfully predicted treatment outcome. Molecular Oncology. 12(5). 594–601. 1 indexed citations
15.
Peled, Nir, Laila C. Roisman, Benjamin Miron, et al.. (2017). Subclonal Therapy by Two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR -Mutated Lung Cancer. Journal of Thoracic Oncology. 12(7). e81–e84. 40 indexed citations
16.
Miron, Benjamin, Nir Peled, Gabi Tarcic, et al.. (2016). Functional profiling of oncogenic mutations in lung cancer patients (NCT02274025) - interim results. Annals of Oncology. 27. vi412–vi412. 1 indexed citations
17.
Miron, Benjamin, Benjamin T. Ristau, Jeffrey Tomaszewski, et al.. (2016). Biology is Destiny: A Case of Adrenocortical Carcinoma Diagnosed and Resected at Inception in a Patient Under Close Surveillance for Lung Cancer. Urology Case Reports. 9. 9–11.
18.
Ilson, David H., David P. Kelsen, Manish A. Shah, et al.. (2010). A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. Cancer. 117(7). 1409–1414. 69 indexed citations
19.
Ilson, David H., Manjit S. Bains, Nabil P. Rizk, et al.. (2009). Phase II trial of preoperative bevacizumab (Bev), irinotecan (I), cisplatin (C), and radiation (RT) in esophageal adenocarcinoma: Preliminary safety analysis. Journal of Clinical Oncology. 27(15_suppl). 4573–4573. 8 indexed citations
20.
Ku, Geoffrey Y., et al.. (2008). Cetuximab (C225) plus irinotecan/cisplatin (CPT/Cis) for CPT/Cis-refractory esophageal cancer. Journal of Clinical Oncology. 26(15_suppl). 15580–15580. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nick van Dijk Breakdown of academic impact, for papers by Xiaoliang Zhu Breakdown of academic impact, for papers by Victoria Hinder Breakdown of academic impact, for papers by Kimiharu Takamatsu Breakdown of academic impact, for papers by Wenyu Zhai Breakdown of academic impact, for papers by Sarah Scagliarini Breakdown of academic impact, for papers by Michele Sisani Breakdown of academic impact, for papers by Serena Hilman Breakdown of academic impact, for papers by Urbano Anido Herranz Breakdown of academic impact, for papers by Natalie Q. Wang
Rankless by CCL
2026